Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants

• Published in: Clinical pharmacokinetics Vol. 60; no. 12; pp. 1591 - 1604
• Main Authors: Ganguly, Samit, Edginton, Andrea N., Gerhart, Jacqueline G., Cohen-Wolkowiez, Michael, Greenberg, Rachel G., Gonzalez, Daniel
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2021; Springer Nature B.V
• Subjects: Adolescent; Adult; Adults; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotics; Child; Child, Preschool; Creatinine; Digitization; Drug dosages; Enzymes; FDA approval; Gestational age; Glomerular Filtration Rate; Humans; Infant; Infant, Newborn; Infections; Internal Medicine; Intraabdominal Infections; Kidney; Medicine; Medicine & Public Health; Meropenem; Metabolism; Metabolites; Middle Aged; Models, Biological; Original Research Article; Patients; Pediatrics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Physiology; Plasma; Software; Young Adult; United States > US
• ISSN: 0312-5963; 1179-1926; 1179-1926
• DOI: 10.1007/s40262-021-01046-6

Background Meropenem is a broad-spectrum carbapenem antibiotic approved by the US Food and Drug Administration for use in pediatric patients, including treating complicated intra-abdominal infections in infants < 3 months of age. The impact of maturation in glomerular filtration rate and tubular secretion by renal transporters on meropenem pharmacokinetics, and the effect on meropenem dosing, remains unknown. We applied physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of meropenem in preterm and term infants. Methods An adult meropenem PBPK model was developed in PK-Sim ® (Version 8) and scaled to infants accounting for renal transporter ontogeny and glomerular filtration rate maturation. The PBPK model was evaluated using 645 plasma concentrations from 181 infants (gestational age 23–40 weeks; postnatal age 1–95 days). The PBPK model-based simulations were performed to evaluate meropenem dosing in the product label for infants < 3 months of age treated for complicated intra-abdominal infections. Results Our model predicted plasma concentrations in infants in agreement with the observed data (average fold error of 0.90). The PBPK model-predicted clearance in a virtual infant population was successfully able to capture the post hoc estimated clearance of meropenem in this population, estimated by a previously published model. For 90% of virtual infants, a 4-mg/L target plasma concentration was achieved for > 50% of the dosing interval following product label-recommended dosing. Conclusions Our PBPK model supports the meropenem dosing regimens recommended in the product label for infants <3 months of age.